Compare
Lunai Bioworks Inc. vs IGC Pharma, Inc. vs Earth Science Tech, Inc. vs Matinas BioPharma Holdings, Inc.
| Latest fiscal year | Lunai Bioworks Inc. LNAI | IGC Pharma, Inc. IGC | Earth Science Tech, Inc. ETST | Matinas BioPharma Holdings, Inc. MTNB |
|---|---|---|---|---|
| Year ended | 2025-06-30 | 2025-03-31 | 2026-03-31 | 2025-12-31 |
| Revenue | n/a | $1.27M | $35.70M | n/a |
| Revenue growth (YoY) | n/a | -5.5% | +7.8% | n/a |
| Gross margin | n/a | 48.7% | 71.4% | n/a |
| Operating margin | n/a | -585.8% | n/a | n/a |
| Net margin | n/a | -560.3% | 10.2% | n/a |
| Net income | -$178.01M | -$7.12M | $3.63M | -$10.35M |
| EPS (Diluted) | -$1.08 | -$0.09 | $0.012 | -$2.00 |
| Operating cash flow | -$7.87M | -$4.79M | $1.94M | -$7.01M |
| Free cash flow | n/a | -$4.91M | $1.18M | n/a |
| Cash & equivalents | $92.7K | $405.0K | $796.8K | $4.00M |
| Total assets | $8.23M | $8.75M | $8.97M | $7.21M |
| Total liabilities | $29.58M | $2.42M | $1.93M | $2.38M |
| Shareholders' equity | -$21.35M | $6.33M | $7.01M | $4.83M |
| Return on year-end equity | n/a | -112.5% | 51.8% | -214.2% |
| Shares outstanding | 177.39M | 80.88M | 291.32M | 6.41M |
Revenue, most recent five fiscal years
| Fiscal year | Lunai Bioworks Inc. | IGC Pharma, Inc. | Earth Science Tech, Inc. | Matinas BioPharma Holdings, Inc. |
|---|---|---|---|---|
| Latest | $0 Ended 2012-03-31 | $1.27M Ended 2025-03-31 | $35.70M Ended 2026-03-31 | $1.10M Ended 2023-12-31 |
| 1 year earlier | n/a | $1.34M Ended 2024-03-31 | $33.12M Ended 2025-03-31 | $3.19M Ended 2022-12-31 |
| 2 years earlier | n/a | $911.0K Ended 2023-03-31 | $11.95M Ended 2024-03-31 | $33.0K Ended 2021-12-31 |
| 3 years earlier | n/a | $397.0K Ended 2022-03-31 | $48.5K Ended 2023-03-31 | $158.3K Ended 2020-12-31 |
| 4 years earlier | n/a | $898.0K Ended 2021-03-31 | $14.1K Ended 2022-03-31 | $89.8K Ended 2019-12-31 |